Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

@inproceedings{Cohen2015RivaroxabanIA,
  title={Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE},
  author={Hannah Cohen and Caroline J. Dor{\'e} and Simon M Clawson and Beverley J Hunt and David Alan Isenberg and Munther A. Khamashta and Nicola Muirhead},
  booktitle={Lupus},
  year={2015}
}
INTRODUCTION The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism (VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results may not be directly generalizable to patients with APS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

The Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

  • S Schulman, C Kearon
  • N Engl J Med
  • 2012

Similar Papers

Loading similar papers…